Loading clinical trials...
Loading clinical trials...
This is an open-label extension study of another study protocol, MCS-2-US-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-US-a will be eligible for this st...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Health Ever Bio-Tech Co., Ltd.
NCT05989646 · Urinary Incontinence, Daytime Wetting, and more
NCT05574244 · Benign Prostatic Hyperplasia
NCT06798311 · Urinary Incontinence (UI), Lower Urinary Tract Symptoms (LUTS), and more
NCT03297281 · Benign Prostatic Hyperplasia, Anticoagulant Adverse Reaction
NCT07451548 · Lower Urinary Tract Symptoms (LUTS)
David Geffen School of Medicine at UCLA
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions